Ascendis Pharma A/S ADR ASND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASND is a good fit for your portfolio.
News
-
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
-
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
-
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
-
Ascendis Pharma Says FDA Extending Review Period for NDA
-
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
-
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
-
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
Trading Information
- Previous Close Price
- $134.18
- Day Range
- $132.38–136.30
- 52-Week Range
- $85.29–161.00
- Bid/Ask
- $120.18 / $135.89
- Market Cap
- $7.76 Bil
- Volume/Avg
- 107,293 / 371,965
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 879
- Website
- https://www.ascendispharma.com
Valuation
|
Metric
|
ASND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 21.48 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASND
|
|---|---|
Quick Ratio | 0.49 |
Current Ratio | 0.83 |
Interest Coverage | −2.99 |
Quick Ratio
ASND
Profitability
|
Metric
|
ASND
|
|---|---|
Return on Assets (Normalized) | −52.06% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −61.61% |
Return on Assets
ASND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Mrpqbcjhkc | Xsts | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xkypgnnvl | Shjhd | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mgbgnxgp | Mxjdlx | $114.0 Bil | |||
| Moderna Inc
MRNA
| Qqzsxsrh | Nttg | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ybvnvmjj | Srvnwj | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Ctqxzxncx | Wrpv | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Yxdvpbqv | Gsdd | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ktltytlt | Flfqpdp | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Dblmfwjc | Fsg | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Zcnrnwlnr | Rftspv | $11.6 Bil |